-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Corfu Medical announced that the company intends to acquire 100% equity of Acorn Trading and sign the "Terms Agreement" to promote related equity acquisitions
.
According to the staff, after the signing of the agreement, Corfu Medical plans to use "BeiBeiJia" as a sub-brand of rehabilitation assistive products.
Professional clinical academic research and product upgrade development
.
And combined with the company's deep research and development accumulation in the field of multi-parameter health monitoring, to create a series of posture correction, shaping, physiotherapy and wearable medical monitoring products based on medical technology
.
According to the data, Acorn Trading is a wholly-owned subsidiary of DRTV, which mainly operates products such as "BaiBaiJia" posture correction, shaping, massage, and physiotherapy
.
According to the aggregated data from Tmall and JD.
com's related stores of "Beibeijia", its sales (including tax) in the past three years were 176 million yuan, 266 million yuan, and 215 million yuan, respectively.
Sales from January to October 2021 (Including tax) is about 141 million yuan
.
Regarding the acquisition of Acorn Trading by Corfu Medical, the industry believes that in addition to helping the former to create a series of posture correction, shaping, physiotherapy and wearable medical monitoring products based on medical technology, it will further improve the structure of rehabilitation products.
In addition; based on Corfu Medical’s rich experience and comprehensive operating capabilities in the field of Internet sales, as well as the extensive layout of offline pharmacies, supermarkets and other channels, the "Beibeijia" series of rehabilitation products will also be expected to become an important revenue and profit growth for the company Point
.
It is worth noting that on the same day, Corfu Medical also disclosed that it intends to use its own funds to acquire 27.
0875% equity of Jirui Medical held by Chen Jianguo, 16.
2671% of Jirui Medical held by Ningbo Waige, and Jirui Medical held by Niu Qiaoli 2.
6% equity, 6.
8493% equity of Jirui Medical held by Shanghai Jizhong and 1.
25% equity of Jirui Medical held by Jirui Investment
.
It is understood that Jirui Medical is a high-tech enterprise, specialized and new enterprise integrating R&D, production and sales of intelligent rehabilitation assistive devices such as electric wheelchairs, manual wheelchairs, and old-fashioned scooters. .
At present, Jirui Medical has 6 invention patents, 51 utility model patents, 30 appearance patents, 70 models of electric wheelchairs that have obtained medical device registration certificates, and 20 models of manual wheelchairs.
It has a complete intellectual property system and dazzling Technology research and development capabilities
.
Through the acquisition of Jirui Medical, the industry expects that Corfu Medical will supplement the vacancies in independent research and development and production capacity of wheelchairs, mobility aids and other products
.
In fact, according to the staff, Jirui Medical's Nantong production base has been put into use in 2021, and the annual design production capacity has been increased to 250,000 units
.
Therefore, this acquisition will help increase the overall revenue scale and comprehensive strength of Corfu's medical rehabilitation assistive products, increase the proportion of its own brand and self-manufactured products, and further consolidate and enhance the company's core competitiveness
.
In general, with the accelerated aging of China's population, the number of people in demand for rehabilitation assistive products is rising sharply, and its market is also expanding
.
After the above two acquisitions are completed, analysts believe that Corfu Medical's annual sales revenue in the field of rehabilitation assistive devices can achieve more than 600 million yuan
.
At the same time, it will also be able to integrate the entire industry chain of rehabilitation aids, give play to the synergy between the two parties, cultivate new profit growth points, and further consolidate the competitiveness of Corfu Medical in the domestic rehabilitation aid industry
.
It is reported that there are currently a large number of companies in the domestic rehabilitation assistive device industry, and a number of leading companies have emerged in their respective segments, but the overall market share is still very low.
Therefore, Corfu Medical will further enhance the company's market competitiveness through this merger and acquisition.
.
.
According to the staff, after the signing of the agreement, Corfu Medical plans to use "BeiBeiJia" as a sub-brand of rehabilitation assistive products.
Professional clinical academic research and product upgrade development
.
And combined with the company's deep research and development accumulation in the field of multi-parameter health monitoring, to create a series of posture correction, shaping, physiotherapy and wearable medical monitoring products based on medical technology
.
According to the data, Acorn Trading is a wholly-owned subsidiary of DRTV, which mainly operates products such as "BaiBaiJia" posture correction, shaping, massage, and physiotherapy
.
According to the aggregated data from Tmall and JD.
com's related stores of "Beibeijia", its sales (including tax) in the past three years were 176 million yuan, 266 million yuan, and 215 million yuan, respectively.
Sales from January to October 2021 (Including tax) is about 141 million yuan
.
Regarding the acquisition of Acorn Trading by Corfu Medical, the industry believes that in addition to helping the former to create a series of posture correction, shaping, physiotherapy and wearable medical monitoring products based on medical technology, it will further improve the structure of rehabilitation products.
In addition; based on Corfu Medical’s rich experience and comprehensive operating capabilities in the field of Internet sales, as well as the extensive layout of offline pharmacies, supermarkets and other channels, the "Beibeijia" series of rehabilitation products will also be expected to become an important revenue and profit growth for the company Point
.
It is worth noting that on the same day, Corfu Medical also disclosed that it intends to use its own funds to acquire 27.
0875% equity of Jirui Medical held by Chen Jianguo, 16.
2671% of Jirui Medical held by Ningbo Waige, and Jirui Medical held by Niu Qiaoli 2.
6% equity, 6.
8493% equity of Jirui Medical held by Shanghai Jizhong and 1.
25% equity of Jirui Medical held by Jirui Investment
.
It is understood that Jirui Medical is a high-tech enterprise, specialized and new enterprise integrating R&D, production and sales of intelligent rehabilitation assistive devices such as electric wheelchairs, manual wheelchairs, and old-fashioned scooters. .
At present, Jirui Medical has 6 invention patents, 51 utility model patents, 30 appearance patents, 70 models of electric wheelchairs that have obtained medical device registration certificates, and 20 models of manual wheelchairs.
It has a complete intellectual property system and dazzling Technology research and development capabilities
.
Through the acquisition of Jirui Medical, the industry expects that Corfu Medical will supplement the vacancies in independent research and development and production capacity of wheelchairs, mobility aids and other products
.
In fact, according to the staff, Jirui Medical's Nantong production base has been put into use in 2021, and the annual design production capacity has been increased to 250,000 units
.
Therefore, this acquisition will help increase the overall revenue scale and comprehensive strength of Corfu's medical rehabilitation assistive products, increase the proportion of its own brand and self-manufactured products, and further consolidate and enhance the company's core competitiveness
.
In general, with the accelerated aging of China's population, the number of people in demand for rehabilitation assistive products is rising sharply, and its market is also expanding
.
After the above two acquisitions are completed, analysts believe that Corfu Medical's annual sales revenue in the field of rehabilitation assistive devices can achieve more than 600 million yuan
.
At the same time, it will also be able to integrate the entire industry chain of rehabilitation aids, give play to the synergy between the two parties, cultivate new profit growth points, and further consolidate the competitiveness of Corfu Medical in the domestic rehabilitation aid industry
.
It is reported that there are currently a large number of companies in the domestic rehabilitation assistive device industry, and a number of leading companies have emerged in their respective segments, but the overall market share is still very low.
Therefore, Corfu Medical will further enhance the company's market competitiveness through this merger and acquisition.
.
